Parkinson disease presents multifaceted motor and non-motor challenges that severely impair patient functional independence. Among these complications, painful foot dystonia stands out as an agonizing and common symptom. Patients frequently experience involuntary muscle contractions, clawing toes, and painful inversion of the foot during motor OFF periods. While standard dopaminergic medications address generalized motor deficits, they often fail to relieve focal lower limb spasms. Consequently, clinicians require targeted local interventions that deliver durable analgesia without increasing systemic side effects. A breakthrough randomized, double-blind, placebo-controlled trial published in Neurology: Clinical Practice now demonstrates that onabotulinumtoxinA offers significant, long-lasting relief for these patients.

Clinical Burden of Painful Foot Dystonia in Daily Practice

Lower extremity dystonia represents one of the most disabling focal motor manifestations in Parkinson disease. Although physicians often encounter morning foot posturing before the first levodopa dose, spasms can also arise unpredictably between regular doses. These sustained contractions force the toes into painful flexion and pull the hindfoot into severe inversion. Therefore, patients experience intense physical pain, recurrent skin breakdown, postural instability, and gait impairment. Furthermore, ambulatory individuals face an elevated risk of falls and secondary fractures. Routine oral pharmacotherapy frequently proves ineffective because escalating dopaminergic dosages can trigger generalized dyskinesias or orthostatic hypotension. As a result, physicians struggle to manage focal foot symptoms through systemic pharmacological adjustments alone. This therapeutic ceiling highlights the urgent clinical need for targeted intramuscular modalities that reliably soothe hyperactive peripheral muscles.

Design and Methodology of the Landmark Controlled Trial

To establish definitive evidence, investigators conducted a rigorous single-center, double-blind, placebo-controlled clinical trial. The study enrolled thirty-three adult participants with unilateral Parkinson disease and medically refractory foot dystonia. Researchers randomly allocated sixteen participants to receive onabotulinumtoxinA and seventeen participants to receive an identical placebo. The clinical team utilized a standardized guided injection protocol that precisely targeted three critical dystonic muscles: the tibialis posterior, extensor hallucis longus, and flexor digitorum brevis. A total fixed dose of 100 units was distributed across these affected muscle groups. Crucially, the protocol incorporated anatomical and electromyographic guidance to ensure maximal target accuracy. Investigators monitored participants prospectively over a 12-week double-blind period, assessing clinical responses at week 6 and week 12, followed by a subsequent 12-week open-label extension phase.

Evaluating Analgesic Efficacy on Standardized Pain Scales

The primary outcome specifically assessed the change from baseline in dystonia-related pain using Item 5 of the King's Parkinson's Disease Pain Scale. Additionally, researchers tracked secondary outcomes, including the King's Parkinson's Disease Pain Scale Domain 3 total score, Visual Analogue Scale pain scores, and responder rates defined by at least a thirty percent pain reduction. At the week 6 mark, participants receiving onabotulinumtoxinA achieved a statistically significant reduction in pain scores compared to those receiving placebo. The mean score difference demonstrated substantial clinical meaningfulness. Moreover, the therapeutic benefits persisted robustly through week 12 without therapeutic attenuation. Participants treated with active neurotoxin experienced marked decreases in both pain severity and spasm frequency. Consequently, the trial firmly verified that peripheral chemodenervation provides robust, verifiable relief for focal neuropathic and musculoskeletal distress.

Impact on Motor Performance and Quality of Life

Beyond isolated pain relief, the investigators examined broader functional outcomes to assess real-world patient benefits. They evaluated motor impairment and motor complications using Parts III and IV of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Furthermore, clinicians recorded Clinical Global Impression ratings alongside validated patient-reported quality of life instruments. Notably, patients in the active treatment group reported substantial improvements in daily mobility, unencumbered ambulation, and footwear tolerance. By relieving involuntary toe flexion and hindfoot inversion, the localized injections restored a more physiological plantar weight-bearing platform. Thus, participants experienced fewer gait interruptions during daytime activities. Because onabotulinumtoxinA acts locally at the motor endplate, it avoids central dopaminergic destabilization. These positive motor and subjective findings confirm that reducing focal discomfort directly enhances overall emotional and functional well-being.

Safety Profile and Procedural Precision with Chemodenervation

Therapeutic safety remains paramount when managing elderly patients with neurodegenerative conditions. Throughout both the double-blind and open-label extension phases, onabotulinumtoxinA maintained an exceptional safety and tolerability profile. Mild, transient muscle weakness represents the primary theoretical risk of botulinum toxin in the lower limb. However, precisely guided dosing prevented significant focal paresis or new functional instability among treated individuals. Systemic adverse reactions did not occur, and no participant withdrew due to injection-related complications. Clinicians must note that accurate anatomical localisation is essential for minimizing off-target diffusion into neighboring foot stabilizers. By combining electromyographic localization with structured dosing protocols, practitioners can optimize local therapeutic delivery safely. Therefore, the procedure provides an extraordinarily dependable outpatient option for movement disorder specialists managing treatment-refractory spasms.

Translating Clinical Evidence into Practical Neurology Workflows

These findings provide clear guidance for outpatient neurology clinics treating complicated Parkinson disease. Clinicians should systematically screen patients for focal foot posturing, particularly when patients report unyielding lower extremity discomfort during OFF states. When adjustments to oral dopaminergic therapy fail or induce intolerable dyskinesias, clinicians should promptly consider onabotulinumtoxinA. The protocol used in this trial demonstrates that a modest dose of 100 units divided among the tibialis posterior, extensor hallucis longus, and flexor digitorum brevis achieves sustained therapeutic control. Additionally, scheduling repeat evaluations at 12-week intervals matches the expected duration of neurotoxin efficacy. By integrating targeted injections into multidisciplinary treatment algorithms alongside physical therapy, clinicians can decisively reduce discomfort, prevent gait deterioration, and improve long-term ambulatory independence.

Frequently Asked Questions

What causes painful foot dystonia in patients with Parkinson disease?

Painful foot dystonia arises from abnormal basal ganglia signaling that triggers sustained, involuntary contractions in lower extremity muscles. These spasms commonly emerge during OFF periods when dopaminergic medication concentrations drop, causing severe plantar flexion, toe clawing, and painful foot inversion that impairs ambulation and stability.

Which specific muscles receive onabotulinumtoxinA injections for foot dystonia?

The randomized clinical trial utilized a standardized guided protocol targeting three specific muscles: the tibialis posterior, extensor hallucis longus, and flexor digitorum brevis. Targeting these muscles corrects the pathological inversion and abnormal toe clawing that generate severe dystonic pain in affected individuals.

How long does pain relief typically last after botulinum toxin injection?

Relief typically becomes evident within two weeks following injection and peaks around six weeks post-treatment. The controlled trial demonstrated sustained pain reduction through twelve weeks, indicating that patients generally require repeat injection sessions every three to four months to maintain consistent therapeutic benefits.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment and should not be relied upon as a substitute for professional clinical judgment. Consult a qualified healthcare professional regarding any medical condition or before implementing any clinical decision. Refer to the latest local and national guidelines for clinical practice.

References

Mahjoub Y et al. OnabotulinumtoxinA for Painful Foot Dystonia in Parkinson Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Neurol Clin Pract. 2026 Dec. doi: 10.1212/CPJ.0000000000200659. PMID: 42753227.

Jocson A, Lew M. Use of botulinum toxin in Parkinson's disease. Parkinsonism Relat Disord. 2019;59:57-64. doi: 10.1016/j.parkreldis.2018.12.002.

Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826. doi: 10.1212/WNL.0000000000002560.